June 2026– date –
-
Boltz Forms AI Drug Discovery Partnership with Takeda to Boost Molecular Design with Novel Biomolecular Foundation Models
FirstWord HEALTHTECH Japan Overview Boltz has announced a strategic AI drug discovery partnership with Takeda Pharmaceutical Company. This collaboration will integrate Boltz's new biomolecular foundation models, BoltzMol-1 for small mole... -
Novo Nordisk’s Oral Wegovy Approved in UK, Becoming Europe’s First Oral GLP-1 Obesity Treatment
Clinical Research News UK Overview Novo Nordisk's oral GLP-1 receptor agonist, Wegovy (semaglutide tablet), has received approval in the UK, marking its entry as the first oral obesity medication in Europe. This approval is expected to s... -
Antibody-Drug Conjugate (ADC) Field Enters Era of Diversification in 2025: 130 New ADC Candidates Advance to Clinical Development, Total Reaches 2,334
ChemExpress (citing Beacon ADC database) China Overview In 2025, the Antibody-Drug Conjugate (ADC) field experienced a significant paradigm shift, transitioning from platform validation to an era of diversification. The total number of t... -
Solu Therapeutics’ STX-0712 with CyTAC™ Technology Granted FDA Fast Track for Relapsed or Refractory CMML
Pharma News (citing Solu Therapeutics) USA Overview Solu Therapeutics announced that STX-0712, utilizing its CyTAC™ technology, received FDA Fast Track designation for relapsed or refractory chronic myelomonocytic leukemia (CMML). STX-07... -
NovaBridge Biosciences’ Givastomig Secures FDA Fast Track for HER2-Negative Metastatic Gastric Cancer
Cancer Network (citing NovaBridge Biosciences) USA Overview NovaBridge Biosciences' CLDN18.2 x 4-1BB bispecific antibody, givastomig, has received FDA Fast Track designation for HER2-negative metastatic gastric cancer. This designation i... -
Insilico Medicine Initiates Phase 1 Trial for AI-Designed Brain-Penetrant NLRP3 Inhibitor ISM8969 for Neuroinflammation
World Pharma Today Hong Kong Overview Insilico Medicine has completed dosing of the first patient in a Phase 1 trial for ISM8969, an AI-designed brain-penetrant NLRP3 inhibitor targeting neuroinflammatory and CNS diseases like Parkinson'... -
Oral GLP-1 Receptor Agonist Elecoglipron Achieves Up to 11.8% Weight Loss and 7% Blood Sugar Reduction in Phase 2b Trials
Medical News Today (citing The Lancet) International Overview Once-daily oral GLP-1 receptor agonist elecoglipron demonstrated significant efficacy in its Phase 2b SOLSTICE clinical trial. Obese and overweight adults achieved up to an 11... -
Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for SMA Patients with Suboptimal Gene Therapy Response
Cure SMA USA Overview Biogen's investigational spinal muscular atrophy (SMA) therapy, salanersen, has received Breakthrough Therapy Designation from the FDA. This designation is based on promising Phase 1b data in pediatric SMA patients ... -
Biologically-Driven Generative Chemistry: Advanced Deep Generative Models for De Novo Drug Design
ChemRxiv International Overview A new preprint study reviews biologically-driven generative chemistry, emphasizing deep generative models for novel molecular design. These models now integrate diverse biological data, including bioassays... -
Isomorphic Labs Secures $2.1B Series B Funding to Scale AI Drug Discovery Platform ‘IsoDDE’
IntuitionLabs UK Overview Isomorphic Labs, a Google DeepMind spin-off, has successfully raised $2.1 billion in Series B funding to globally expand its AI-driven drug discovery platform, 'IsoDDE,' and advance multiple drug programs. Built...
